drugset / Trial / NCT05448001

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

NCT05448001

Phase 3 Completed 329 enrolled Onconic Therapeutics Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients with Gastric Ulcer

Timeline

Start
2022-09-19
Primary completion
2024-07-10
Completion
2024-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject JP-1366 Unknown 20 mg
Comparator Lansoprazole Other / unclassified 30 mg

Indications